Expression of cell-surface and cytoplasmic markers for the diagnosis of AML and MPAL
| Diagnosis of AML . | . |
|---|---|
| Diagnosis of AML | |
| Precursor marker | CD34, CD117, HLA-DR |
| Myeloid markers | Cytoplasmic MPO, CD33, CD13 |
| Myeloid maturation markers | CD11b, CD15, CD64, CD65 |
| Monocytic markers | CD14, CD36, CD64, CD4, CD38, CD11c |
| Megakaryocytic markers | CD41 (glycoprotein IIb/IIIa), CD61 (glycoprotein IIIa), CD36 |
| Erythroid markers | CD235a (glycophorin A), CD71, CD36 |
| Diagnosis of MPAL | |
| Myeloid lineage | MPO (flow cytometry, immunohistochemistry or cytochemistry), or monocytic differentiation (at least 2 of the following: non-specific esterase cytochemistry, CD11c, CD14, CD64, lysozyme), or at least two myeloid markers, ie, CD177, CD33, CD13 |
| T-lineage | Strong cytoplasmic CD3 (with antibodies to CD3 ε chain) or surface CD3 |
| B-lineageg | Strong CD19 with at least one of the following strongly expressed: cytoplasmic CD79a, cCD22 or CD10, or weak CD19 with at least two of the following strongly expressed: CD79a, cCD22 or CD10 |
| Core MRD markers | |
| CD34, CD117, CD45, CD33, CD13, CD56, CD7, HLA-DR If monocytic: CD64, CD11b, CD4 (in addition) |
| Diagnosis of AML . | . |
|---|---|
| Diagnosis of AML | |
| Precursor marker | CD34, CD117, HLA-DR |
| Myeloid markers | Cytoplasmic MPO, CD33, CD13 |
| Myeloid maturation markers | CD11b, CD15, CD64, CD65 |
| Monocytic markers | CD14, CD36, CD64, CD4, CD38, CD11c |
| Megakaryocytic markers | CD41 (glycoprotein IIb/IIIa), CD61 (glycoprotein IIIa), CD36 |
| Erythroid markers | CD235a (glycophorin A), CD71, CD36 |
| Diagnosis of MPAL | |
| Myeloid lineage | MPO (flow cytometry, immunohistochemistry or cytochemistry), or monocytic differentiation (at least 2 of the following: non-specific esterase cytochemistry, CD11c, CD14, CD64, lysozyme), or at least two myeloid markers, ie, CD177, CD33, CD13 |
| T-lineage | Strong cytoplasmic CD3 (with antibodies to CD3 ε chain) or surface CD3 |
| B-lineageg | Strong CD19 with at least one of the following strongly expressed: cytoplasmic CD79a, cCD22 or CD10, or weak CD19 with at least two of the following strongly expressed: CD79a, cCD22 or CD10 |
| Core MRD markers | |
| CD34, CD117, CD45, CD33, CD13, CD56, CD7, HLA-DR If monocytic: CD64, CD11b, CD4 (in addition) |